ProCE Banner Activity


Nursing Perspectives on the Impact of Immune Checkpoint Inhibitors in Early Stages of Cancer


Watch this on-demand webcast from a live webinar on the role of immune checkpoint inhibitors in early stages of cancer. 

Nurses: 1.50 Nursing contact hours

Released: July 17, 2023

Expiration: July 16, 2024

No longer available for credit.



Marianne Davies

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager, Care Signature
Oncology Service Line
Yale New Haven Health
Oncology Nurse Practitioner- Senior APP II
Smilow Cancer Hospital, Yale-New Haven
Yale Comprehensive Cancer Center
Associate Professor
Yale University School of Nursing
New Haven, Connecticut

Ronan J. Kelly

Ronan J. Kelly, MD, MBA

Director, Charles A. Sammons
Cancer Center                           
W.W. Caruth Jr. Endowed Chair
of Immunology                              
Baylor University Medical Center
Chief, Oncology Baylor Scott & White Health System (NTx)   
Clinical Professor                       
Texas A&M University
College of Medicine                                  
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This educational program is intended for oncology nurses and other healthcare professionals who care for patients with cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of oncology nurses to understand and explain available clinical data on novel and emerging approaches for early stages of cancer and how these data and treatments will affect clinical outcomes, as well as how to promote health equity among patients with cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate key clinical data and current indications for immune checkpoint inhibitor–based neoadjuvant or adjuvant therapy in patients with earlier stages of solid tumor cancers

  • Apply a focused nursing assessment navigating the implications of immuno-oncology in early stages of cancer and knowledge of adverse events unique to immune checkpoint inhibitors

  • Communicate with patients about the expectations of early treatment with ICIs on their overall prognosis, along with the importance of frequent monitoring and early reporting of immune-related adverse events

  • Identify patients most likely to benefit from treatment with immune checkpoint inhibitor therapy or enrollment on clinical trials, considering existing barriers that create racial and socioeconomic disparities in care


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Marianne Davies, DNP, ACNP, FAAN, has no relevant financial relationships to disclose.

Ronan Kelly, MD, MBA: consultant/advisor/speaker: Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Grail, Ipsen, Merck, Novartis, Novocure, Takeda, Toray; researcher: Lilly.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 17, 2023, through July 16, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.